US3232836A - Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine - Google Patents
Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine Download PDFInfo
- Publication number
- US3232836A US3232836A US835451A US83545159A US3232836A US 3232836 A US3232836 A US 3232836A US 835451 A US835451 A US 835451A US 83545159 A US83545159 A US 83545159A US 3232836 A US3232836 A US 3232836A
- Authority
- US
- United States
- Prior art keywords
- glucosamine
- body surface
- healing
- intravenous administration
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
Definitions
- This invention relates to a new and useful process of promoting healing in the human body. More particularly, it relates to a new process of promoting healing in the human which comprises administering glucosamine and/ or glucosamine derivatives to a person with a wound of the body surface. It also relates to compositions useful therefor.
- This application is a continuation-in-part of our copending application Serial No. 795,617, filed on February 26, 1959, now abandoned.
- the healing of wounds of the body surface whether caused by trauma or surgery often times presents considerable dificulty, as described in numerous articles appearing in the medical literature. Many persons exhibit a slow rate of healing during which time considerable care must be taken to avoid the possibility of infection. Even with persons of normal healing rate, protection against infection must be provided, necessitating exacting care by medical personnel.
- the present invention provides a new and effective process of facilitating the healing of Wounds of the body surface which materially reduces the time during which the possibility of infection is greatest as well as the time periods of close medical care and supervision. Other beneficial results of the present process are obvious from the following dis closure.
- the process of the present invention comprises administering an effective amount of glucosamine and/or glucosamine derivatives to a subject with a wound of the body surface. While beneficial results will be noted with even lesser amounts, it is usually desirable to administer the glucosamine compound at a dosage of at least from about to about 20 grams per day for best results. Often times it is found advantageous to administer the glucosamine compound at dosages as high as 200 grams per day and even higher.
- the physician will indicate daily dosage of the instant therapeutic agents.
- the dosage and the route of administration will depend upon the extent of the wound and the healing rate of the individual patient.
- the present therapeutic agents may be administered orally or locally, i.e. into the Wound, and, at other times, parenterally, that is intravenously.
- these routes of administration may be employed concurrently to maintain an effective level of glucosamine compound in the subject patient.
- the glucosamine compound may be administered to a patient orally at a dosage of from 10 to 20 grams per day for a period of four to five days before surgery, followed by intravenous administration at a dosage of between 100 to 200 grams in parenteral fluids, usually isotonic slaine, for four to five days postoperatively and then oral administration, as needed, of from 10 to 20 grams per day, usually for an additional four to five days.
- the present invention contemplates the use of glucosamine, and/or glucosamine derivatives, such as lower N-alkanoylglucosamine, e.g. N-acetylglucosamine, phosphorylatedglucosamines, such as N-acetylglucosamine-6- phosphate, and glucosamine-G-phosphate, salt of glucosamine with pharmaceutically-acceptable acids, such as hydrochloric, phosphoric, citric, gluconic, acetic, malic and the like.
- glucosamine derivative is N-acetylglucosamine.
- the therapeutic agent is conveniently administered in the form of a suspension or solution, although it may also be administered as tablets or capsules.
- suspensions or solutions of the therapeutic agent in pharmaceuticaly acceptable liquid media are particularly effective.
- liquid media are well known in the art, for example, water, aqueous glycols, sugar solutions and the like which may contain conventional flavoring and coloring agents.
- Tablets and capsules may be prepared from mixtures of the present compounds with well known pharmaceutical excipients such as starch, sugar, tapioca, certain forms of clay, and the like.
- the present compounds are administered in isotonic solutions, such as isotonic saline.
- the present invention provides sterile aqueous compositions for intravenous administration which are prepared by dissolving the selected agent in an isotonic (about 0.1%) saline solution. It is preferred to employ the glucosamine compound at a concentration ranging from about 2% to about 20%, and preferably from about 3% to about 10%. Of course, lower concentrations provide some beneficial results but necessitate the use of extremely large volumes of intravenous solution which is usually not desirable. Higher concentrations, although operable, provide no appreciable advantage and thus are not recommended.
- the present invention also provides sterile solid compositions of glucosamine and/ or glucosarnine derivative together with salt for reconstitution with water to provide the abovedescribed intravenous compositions.
- Such solid compositions should contain a sufficient amount of salt to provide an isotonic saline solution when dissolved in Water, that is, an isotonic amount of salt.
- the solid compositions preferably contain salt and glucosarnine compound in a weight ratio ranging from about 1:20 to about 1:200. For example, when one gram of sodium chloride and 50 grams of N-acetylglucosamine aredissolved in one liter of Water, a 5% glucosamine isotonic saline solution is obtained. Other such isotonic solutions of the glucosamine compound are prepared by reconstitution of the present solid compositions.
- the following exemplifies the eflicacy of the present new invention in promoting wound-healing.
- Daily intravenous administration of N-acetylglucosamine in isotonic saline g. dissolved in 3 liters per day) to this patient for 4 days followed by daily oral administration of 20 grams of N-acetylglucosamine for 5 days resulted in a marked improvement in general condition with rapid healing of the wound.
- a process for facilitating healing of a body wound of the body surface which comprises administering intravenously an effective amount of N-acetyl glucosaniine.
- therapeutically effective agents may be co-administered with the present agents, for example, compounds which serve as a source of high-energy phosphorus.
- compounds which serve as a source of high-energy phosphorus are phosphoenolpruvic acid and adenosine phosphates, e.g. mono and di-phosphates, which aid in the phosphorylation of intermediates in the metabolism of carbohydrate.
- Other such therapeutic agents may similarly be employed, e.g. broad spectrum Referemes Cited y the Examine!
- antibiotics such as tetracycline, oxytetracycline ascorbic UNITED STATES PATENTS 3 tyrosmei 2,710,806 6/1955 Gyorgy 99 54 rhe following examples are given by way of illustra- 2 786 051 3/1957 Gyorgy 260 2115 tion and are not to be construed as limitations of the 28O2819 8/1057 Ledemr g 3 I present invention, many variations of which are possible 2832766 4/1558 wolfrom without departing from the spirit or scope thereof. 411 4/1959 HeynS 260 211 Example 1 2,910,408 10/1959 Pope et al. 26021l 2 980 584 4/1961 Hammer 16765 A mixture of 100 g.
- N-acetylglucosamine and 1 g. of 7 sodium chloride is thoroughly blended in a twin shell 299747l 8/1961 Cheney et a1 260' 2472 blender in an ethylene oxide-carbon dioxide atmosphere.
- the mixture is stored in an infusion bottle for reconstitution with one liter of sterile water for intravenous administration.
- 1 part salt to 50 parts glucosamine. 1 part salt to 100 parts glucosamine hydrochloride. 1 part salt to 200 parts glucosamine phosphate.
- Example 111 The procedure of Example 11 is repeated to prepare the following solutions:
Description
United States Patent FACELiTATiNG HEALING 0F BODY SURFACE WOUNDS BY ENTRAVENOUS ADMENISTRATION OF N-ACETYL GLUCOSAMENE, GLUCOSAMINE, 0R PHARMAQEUTECALLY ACQEPTABLE AQEID SALTS OF GLUJOSAMINE Michael Carlozzi, (Irani'ord, NJ and Domenic G. lozzoni, Garden City, N.Y., assignors to Chas. Pfizer & Co., linc., New York, N.Y., a corporation of Delaware No Drawing. Filed Aug. 24, 1959, Ser. No. 835,451
2 Claims. (Cl. 167-65) This invention relates to a new and useful process of promoting healing in the human body. More particularly, it relates to a new process of promoting healing in the human which comprises administering glucosamine and/ or glucosamine derivatives to a person with a wound of the body surface. It also relates to compositions useful therefor. This application is a continuation-in-part of our copending application Serial No. 795,617, filed on February 26, 1959, now abandoned.
The healing of wounds of the body surface whether caused by trauma or surgery often times presents considerable dificulty, as described in numerous articles appearing in the medical literature. Many persons exhibit a slow rate of healing during which time considerable care must be taken to avoid the possibility of infection. Even with persons of normal healing rate, protection against infection must be provided, necessitating exacting care by medical personnel. The present invention provides a new and effective process of facilitating the healing of Wounds of the body surface which materially reduces the time during which the possibility of infection is greatest as well as the time periods of close medical care and supervision. Other beneficial results of the present process are obvious from the following dis closure.
As previously mentioned, the process of the present invention comprises administering an effective amount of glucosamine and/or glucosamine derivatives to a subject with a wound of the body surface. While beneficial results will be noted with even lesser amounts, it is usually desirable to administer the glucosamine compound at a dosage of at least from about to about 20 grams per day for best results. Often times it is found advantageous to administer the glucosamine compound at dosages as high as 200 grams per day and even higher.
The physician will indicate daily dosage of the instant therapeutic agents. The dosage and the route of administration will depend upon the extent of the wound and the healing rate of the individual patient. At times, the present therapeutic agents may be administered orally or locally, i.e. into the Wound, and, at other times, parenterally, that is intravenously. Of course, these routes of administration may be employed concurrently to maintain an effective level of glucosamine compound in the subject patient. For example, the glucosamine compound may be administered to a patient orally at a dosage of from 10 to 20 grams per day for a period of four to five days before surgery, followed by intravenous administration at a dosage of between 100 to 200 grams in parenteral fluids, usually isotonic slaine, for four to five days postoperatively and then oral administration, as needed, of from 10 to 20 grams per day, usually for an additional four to five days.
The present invention contemplates the use of glucosamine, and/or glucosamine derivatives, such as lower N-alkanoylglucosamine, e.g. N-acetylglucosamine, phosphorylatedglucosamines, such as N-acetylglucosamine-6- phosphate, and glucosamine-G-phosphate, salt of glucosamine with pharmaceutically-acceptable acids, such as hydrochloric, phosphoric, citric, gluconic, acetic, malic and the like. A particularly effective, and, for this reason, preferred glucosamine derivative is N-acetylglucosamine. The therapeutic agent is conveniently administered in the form of a suspension or solution, although it may also be administered as tablets or capsules. For oral use, suspensions or solutions of the therapeutic agent in pharmaceuticaly acceptable liquid media are particularly effective. Such liquid media are well known in the art, for example, water, aqueous glycols, sugar solutions and the like which may contain conventional flavoring and coloring agents. Tablets and capsules may be prepared from mixtures of the present compounds with well known pharmaceutical excipients such as starch, sugar, tapioca, certain forms of clay, and the like. For intravenous use, the present compounds are administered in isotonic solutions, such as isotonic saline.
For intravenous use, the present invention provides sterile aqueous compositions for intravenous administration which are prepared by dissolving the selected agent in an isotonic (about 0.1%) saline solution. It is preferred to employ the glucosamine compound at a concentration ranging from about 2% to about 20%, and preferably from about 3% to about 10%. Of course, lower concentrations provide some beneficial results but necessitate the use of extremely large volumes of intravenous solution which is usually not desirable. Higher concentrations, although operable, provide no appreciable advantage and thus are not recommended. The present invention also provides sterile solid compositions of glucosamine and/ or glucosarnine derivative together with salt for reconstitution with water to provide the abovedescribed intravenous compositions. Of course, such solid compositions should contain a sufficient amount of salt to provide an isotonic saline solution when dissolved in Water, that is, an isotonic amount of salt. The solid compositions preferably contain salt and glucosarnine compound in a weight ratio ranging from about 1:20 to about 1:200. For example, when one gram of sodium chloride and 50 grams of N-acetylglucosamine aredissolved in one liter of Water, a 5% glucosamine isotonic saline solution is obtained. Other such isotonic solutions of the glucosamine compound are prepared by reconstitution of the present solid compositions.
As a result of the administration of a glucosamine compound as herein described, in addition to a remarkable improvement in healing time, patients generally show a sense of well being, maintain body weight and, in some instances, unexpected weight gains are obtained. Further, such patients exhibit positive nitrogen balance in place of the usually expected negative balance during immediate postoperative period. Additionally, there is noted a lowering of blood cholesterol.
The following exemplifies the eflicacy of the present new invention in promoting wound-healing. A female patient of 19 years of age and average weight with a mid-thigh amputation of a lower extremity suffered serious postoperative complications and poor wound healing. Daily intravenous administration of N-acetylglucosamine in isotonic saline g. dissolved in 3 liters per day) to this patient for 4 days followed by daily oral administration of 20 grams of N-acetylglucosamine for 5 days resulted in a marked improvement in general condition with rapid healing of the wound.
A male patient of 28 years of age and. average weight with postoperative septicemia and shock due to E. coli was being treated by hypothermia and with an artificial kidney for about three weeks. During this time his abdominal Wound, i.e. the original operative incision, remained opened and gaping. At this time, the patient was treated with N'acetylglucosamine intravenously for 4 days, daily dosage being 100 grams in 3 liters of isotonic saline, followed by oral administration of 20 grams of N-acetylglucosamine daily for 5 days, which resulted in excellent, rapid healing of the wound. Similar results are obtained with glucosamine and other glucos-a- 5 mine derivatives as hereinbefore described with human as well as animal subjects.
Similar results were obtained when the present process was used in the treatment of other surgical patients. A Process for facilitating healing of a Wound Of The results are summarized in the following table: m the body surface which comprises administering intra- [NA G N-acetylglucosamine] 2% glucosamine hydrochloride in 0.1% saline. 20% N-acetylglucosamine in 0.1% saline.
5% glucosamine phosphate in 0.1% saline. 5% glucosamine citrate in 0.1% saline.
10% glucosamine gluconate in 0.1% saline. 3% glucosamine acetate in 0.1% saline.
What is claimed is:
Premperative Serum trans- Blood Urine N Patient Diagnosis and operation treatment Post-operative treatment aminase units cholesterol, gm.
nigrn./l cc.
I. 49 WF Ulccrative colitis, Rx for NAG, 10 gm. daily 1st P.O. day, NAG, 100 Irc-cp. 21 2.4
several weeks with 300 for 4 days. gins. I.V.; 2d R0. day, 1st 19.0. 40 ion mgm. cortisone daily. WAG, 200 8. 3d 4th P.O. 23.. 4 500 No complications. Dis- 1&0. day, NAG, 250 gms. 10th R0. 11 145 .145 charged 11th l.0. day. I.V.; 4th P.O. day, NAG,
200 gms. I.V.
II. 63 CF Perforated peptic ulcer, 3 None NAG, 200 gm. I.V. daily Ire-op. 28 Hi 500 days duration. No comfor 5 days. 1st R0. 47 190 .720 plications. Discharged 4th R0. 26.. 1:3 .300 12th P.O. day. th P.O. l2. 110 100 III. 63 CM Subtotal gastrectomy NAG, 10 gm. daily NAG, 200 gin. I.V. daily Pre-op. 19... 204 .100 chronic duodenal ulcer. for 4 days. for 3 days. 1st PD. 41 210 100 Discharged 8th P.O. day. t P.O. 10 180 Balance No complications. 8th P.O. 4 a. 170 Balance IV. 39 C11... Acute+ohronic cholecystitis None NAG, 200 gm. I.V. daily Pre-op. 24 142 .400 cholecystectomy. No for 3 days. 1st 1.O. 31 100 .400 complications. Discharg- 4th P.O. 20.. 160 100 ed 10th I.O. day. 10th P.O. 8 130 Balance venously from about 100 to about 200 grams of a compound selected from the group consisting of N-acetyl glucosamine, glucosamine and pharmaceutically acceptable acid salts of glucosamine.
2. A process for facilitating healing of a body wound of the body surface which comprises administering intravenously an effective amount of N-acetyl glucosaniine.
As it is obvious to those skilled in the art other therapeutically effective agents may be co-administered with the present agents, for example, compounds which serve as a source of high-energy phosphorus. Exemplary of this type of compound are phosphoenolpruvic acid and adenosine phosphates, e.g. mono and di-phosphates, which aid in the phosphorylation of intermediates in the metabolism of carbohydrate. Other such therapeutic agents may similarly be employed, e.g. broad spectrum Referemes Cited y the Examine! antibioticssuch as tetracycline, oxytetracycline ascorbic UNITED STATES PATENTS 3 tyrosmei 2,710,806 6/1955 Gyorgy 99 54 rhe following examples are given by way of illustra- 2 786 051 3/1957 Gyorgy 260 2115 tion and are not to be construed as limitations of the 28O2819 8/1057 Ledemr g 3 I present invention, many variations of which are possible 2832766 4/1558 wolfrom without departing from the spirit or scope thereof. 411 4/1959 HeynS 260 211 Example 1 2,910,408 10/1959 Pope et al. 26021l 2 980 584 4/1961 Hammer 16765 A mixture of 100 g. of N-acetylglucosamine and 1 g. of 7 sodium chloride is thoroughly blended in a twin shell 299747l 8/1961 Cheney et a1 260' 2472 blender in an ethylene oxide-carbon dioxide atmosphere. The mixture is stored in an infusion bottle for reconstitution with one liter of sterile water for intravenous administration.
Other such mixtures are prepared in the same manner to provide solid compositions containing the following weight proportions of salt to glucose compound:
OTHER REFERENCES Anglesio, E., et al., Effects of Carcinostatic and Other Biologically Active Compounds in the Normal Rat, Cancer Research, vol. 18, No. 1, pp. 113l16 (1959).
Baratella, Sullmpiego di Un Nuovo tipo di Latte in Polvere Integrato Con Fattore Bifidus e Vit. B12 Clinica Pediatrica (Bologna), vol. 40, No. 1, pp. 39-40,
1 part salt to 50 parts glucosamine. 1 part salt to 100 parts glucosamine hydrochloride. 1 part salt to 200 parts glucosamine phosphate.
1 part salt to 20 parts N-acetylglucosamine.
Example II January 1958.
Boas, N., et al.,
vol. 88, No. 3, pp. 454457, March 1955.
Boyer et al., The Enzymes vol. 1, 2nd edition Academrate of intravenously Administered Glucosamine in the Rat, Proc. Soc. Exp. Biol. and Med,
(Other references on following page) Two thousand grams of N-acetylglucosamine is added to 20 liters of 0.1% aqueous saline solution. The resulting solution is filtered through a Seitz filter and stored in infusion bottles each containing one liter of 10% solution. The solution is useful for intravenous administration to human hosts with a wound of the body surface.
Example 111 The procedure of Example 11 is repeated to prepare the following solutions:
20% glucosamine in 0.1% saline. 3% N-acetylglucosainine in 0.1% saline.
5 OTHER REFERENCES 249-265, pages 4, 7-8, 29-34, 257-260 are especially pertinent.
Paschoud, Experimentelle Untersuchungen Zur Heparin-Genese Der Urticaria Pigmentosa, Dermatologica (Basel), vol. 108, No. 46, pp. 361-365 (1954).
Reed, Efiect of Cortisone on the Postive Potentiais Induced by Glucosamine and Amino Purines in the 6 Synovial Cavities of Dogs, Am. J. PhysioL, vol. 168, pp. 820-824 (1952).
Thian et a1., Prophylactic Use of G1ucosamine-Potentiated Antibiotics in Emergency Abdominal and Gas trointestinal Surgery, 1. Louisiana Med. Soc., vol. III, No. 2, pp. 49-50 (February 1959).
LEWIS GOTTS, Primary Examiner.
MORRIS O. WOLK, WILLIAM B. KNIGHT, IRVING MARCUS, Examiners.
Claims (1)
1. A PROCESS FOR FACILITATING HEALING OF A WOUND OF THE BODY SURFACE WHICH COMPRISES ADMINISTERING INTRAVENOUSLY FROM ABOUT 100 TO ABOUT 200 GRAMS OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF N-ACETYL GLUCOSAMINE, GLUCOSAMINE AND PHARMACEUTICALLY ACCEPTABLE ACID SALTS OF GLUCOSAMINE.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US835451A US3232836A (en) | 1959-08-24 | 1959-08-24 | Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine |
| FR819092A FR320M (en) | 1959-08-24 | 1960-08-25 | Compositions facilitating the healing of wounds. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US835451A US3232836A (en) | 1959-08-24 | 1959-08-24 | Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3232836A true US3232836A (en) | 1966-02-01 |
Family
ID=25269534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US835451A Expired - Lifetime US3232836A (en) | 1959-08-24 | 1959-08-24 | Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3232836A (en) |
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3328258A (en) * | 1962-09-10 | 1967-06-27 | Lipha | Anti-microbial therapeutics consisting of nitrofurantoin, tetracycline, and d-glucosamine |
| FR2016182A1 (en) * | 1968-08-22 | 1970-05-08 | Rotta Research Lab | |
| US3903268A (en) * | 1968-02-12 | 1975-09-02 | Lescarden Ltd | Chitin and chitin derivatives for promoting wound healing |
| US3911116A (en) * | 1970-04-13 | 1975-10-07 | Leslie L Balassa | Process for promoting wound healing with chitin derivatives |
| US3914413A (en) * | 1971-02-10 | 1975-10-21 | Leslie L Balassa | Process for facilitating wound healing with N-acetylated partially depolymerized chitin materials |
| US4006224A (en) * | 1975-09-29 | 1977-02-01 | Lescarden Ltd. | Method and agent for treating inflammatory disorders of the gastrointestinal tract |
| US4642340A (en) * | 1981-04-30 | 1987-02-10 | Rotta Research Laboratorium S.P.A. | Stable compounds of glucosamine sulphate |
| US4647453A (en) * | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
| WO1987002244A1 (en) * | 1985-10-08 | 1987-04-23 | Neil Geddes Clarkson Hendry | Tissue growth regulation |
| WO1988004927A1 (en) * | 1986-12-31 | 1988-07-14 | Davirand, Inc. | Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid |
| US4772591A (en) * | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
| WO1994022453A1 (en) * | 1993-03-31 | 1994-10-13 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
| US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
| US6255295B1 (en) | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
| US6271213B1 (en) | 1996-12-23 | 2001-08-07 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue |
| US6358539B1 (en) | 1999-08-20 | 2002-03-19 | Howard Murad | Pharmaceutical compositions for reducing the appearance of cellulite |
| US6440465B1 (en) * | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
| US20030148998A1 (en) * | 2001-02-16 | 2003-08-07 | Cargill, Incorporated | Glucosamine and method of making glucosamine from microbial biomass |
| US6693188B2 (en) | 2001-08-08 | 2004-02-17 | Cargill Incorporated | N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine |
| US20040077055A1 (en) * | 2001-02-16 | 2004-04-22 | Cargill, Incorporated | Glucosamine and method of making glucosamine from microbial biomass |
| US20050003023A1 (en) * | 2002-06-28 | 2005-01-06 | Meisner Lorraine Faxon | Topical composition for the treatment of psoriasis and related skin disorders |
| US20050075597A1 (en) * | 2003-09-12 | 2005-04-07 | Vournakis John N. | Vascular access preservation in hemodialysis patients |
| US20050129787A1 (en) * | 1999-08-20 | 2005-06-16 | Howard Murad | Pharmaceutical compositions and methods for managing connective tissue ailments |
| US20050215774A1 (en) * | 2002-04-02 | 2005-09-29 | Trinkle Jamea R | Chitosan production |
| US20050245482A1 (en) * | 2000-03-15 | 2005-11-03 | Weiyu Fan | Chitosan and method of preparing chitosan |
| WO2005112948A1 (en) * | 2004-05-21 | 2005-12-01 | Tottori University | Drug for remedy or treatment of wound |
| US20060003965A1 (en) * | 2002-11-01 | 2006-01-05 | Fosdick Lawrence D | N-acetyl-d-glucosamine (nag) supplemented food products and beverages |
| US20060058263A1 (en) * | 2002-11-01 | 2006-03-16 | Rogers Brent D | Heat pasturized liquids containing glucosamine |
| US20060172392A1 (en) * | 2001-02-16 | 2006-08-03 | Cargill, Incorporated | Water soluble beta-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same |
| US20060178344A1 (en) * | 2001-02-16 | 2006-08-10 | Cargill, Incorporated | Glucosamine and N-acetylglucosamine and methods of making the same fungal biomass |
| US20060246114A1 (en) * | 2002-11-01 | 2006-11-02 | Rogers Brent D | Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine |
| US20070015822A1 (en) * | 2005-02-22 | 2007-01-18 | Peter Hanson | Methods for selectively treating COX-2 mediated disorders by administering gamma-tocopherol |
| US20070178161A1 (en) * | 2003-03-27 | 2007-08-02 | Qiwang Xu | Use of n-acetryl-d-glucosamine in treating and controlling non-specific inflammations caused by physical or chemical factors |
| US20100323986A1 (en) * | 2001-02-12 | 2010-12-23 | Marine Polymer Technologies, Inc., | Compositions and methods for modulation of vascular structure and/or function |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2710806A (en) * | 1952-04-22 | 1955-06-14 | American Home Prod | Food compositions |
| US2786051A (en) * | 1952-04-18 | 1957-03-19 | American Home Prod | Growth-promoting substances and their recovery |
| US2802819A (en) * | 1953-07-24 | 1957-08-13 | Ciba Pharm Prod Inc | Acylated products |
| US2832766A (en) * | 1952-04-17 | 1958-04-29 | Univ Ohio State Res Found | Sulfated aminopolysaccharides |
| US2884411A (en) * | 1954-07-29 | 1959-04-28 | Corn Products Co | Preparation of a glucosamine |
| US2910408A (en) * | 1956-12-28 | 1959-10-27 | American Home Prod | Production of n-acetylglucosamine |
| US2980584A (en) * | 1957-10-29 | 1961-04-18 | Pfizer & Co C | Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation |
| US2997471A (en) * | 1958-08-18 | 1961-08-22 | Bristol Myers Co | Tetracycline derivatives |
-
1959
- 1959-08-24 US US835451A patent/US3232836A/en not_active Expired - Lifetime
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2832766A (en) * | 1952-04-17 | 1958-04-29 | Univ Ohio State Res Found | Sulfated aminopolysaccharides |
| US2786051A (en) * | 1952-04-18 | 1957-03-19 | American Home Prod | Growth-promoting substances and their recovery |
| US2710806A (en) * | 1952-04-22 | 1955-06-14 | American Home Prod | Food compositions |
| US2802819A (en) * | 1953-07-24 | 1957-08-13 | Ciba Pharm Prod Inc | Acylated products |
| US2884411A (en) * | 1954-07-29 | 1959-04-28 | Corn Products Co | Preparation of a glucosamine |
| US2910408A (en) * | 1956-12-28 | 1959-10-27 | American Home Prod | Production of n-acetylglucosamine |
| US2980584A (en) * | 1957-10-29 | 1961-04-18 | Pfizer & Co C | Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation |
| US2997471A (en) * | 1958-08-18 | 1961-08-22 | Bristol Myers Co | Tetracycline derivatives |
Cited By (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3328258A (en) * | 1962-09-10 | 1967-06-27 | Lipha | Anti-microbial therapeutics consisting of nitrofurantoin, tetracycline, and d-glucosamine |
| US3903268A (en) * | 1968-02-12 | 1975-09-02 | Lescarden Ltd | Chitin and chitin derivatives for promoting wound healing |
| FR2016182A1 (en) * | 1968-08-22 | 1970-05-08 | Rotta Research Lab | |
| US3911116A (en) * | 1970-04-13 | 1975-10-07 | Leslie L Balassa | Process for promoting wound healing with chitin derivatives |
| US3914413A (en) * | 1971-02-10 | 1975-10-21 | Leslie L Balassa | Process for facilitating wound healing with N-acetylated partially depolymerized chitin materials |
| US4006224A (en) * | 1975-09-29 | 1977-02-01 | Lescarden Ltd. | Method and agent for treating inflammatory disorders of the gastrointestinal tract |
| US4642340A (en) * | 1981-04-30 | 1987-02-10 | Rotta Research Laboratorium S.P.A. | Stable compounds of glucosamine sulphate |
| US4647453A (en) * | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
| US4772591A (en) * | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
| WO1987002244A1 (en) * | 1985-10-08 | 1987-04-23 | Neil Geddes Clarkson Hendry | Tissue growth regulation |
| WO1988004927A1 (en) * | 1986-12-31 | 1988-07-14 | Davirand, Inc. | Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid |
| US5364845A (en) * | 1993-03-31 | 1994-11-15 | Nutramax Laboratories, Inc. | Glucosamine, chondroitin and manganese composition for the protection and repair of connective tissue |
| US6492349B1 (en) | 1993-03-31 | 2002-12-10 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
| US5587363A (en) * | 1993-03-31 | 1996-12-24 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
| AU688313B2 (en) * | 1993-03-31 | 1998-03-12 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
| WO1994022453A1 (en) * | 1993-03-31 | 1994-10-13 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
| US20030216348A1 (en) * | 1996-12-23 | 2003-11-20 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan, and S-Adenosylmethionine composition for the treatment and repair of connective tissue |
| US6255295B1 (en) | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
| US6271213B1 (en) | 1996-12-23 | 2001-08-07 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue |
| US6583123B2 (en) | 1996-12-23 | 2003-06-24 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue |
| US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
| US5972999A (en) * | 1997-01-22 | 1999-10-26 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
| US6358539B1 (en) | 1999-08-20 | 2002-03-19 | Howard Murad | Pharmaceutical compositions for reducing the appearance of cellulite |
| US20050129787A1 (en) * | 1999-08-20 | 2005-06-16 | Howard Murad | Pharmaceutical compositions and methods for managing connective tissue ailments |
| US6676977B2 (en) | 1999-08-20 | 2004-01-13 | Howard Murad | Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| US20050245482A1 (en) * | 2000-03-15 | 2005-11-03 | Weiyu Fan | Chitosan and method of preparing chitosan |
| US7413881B2 (en) | 2000-03-15 | 2008-08-19 | Cargill, Incorporated | Chitosan and method of preparing chitosan |
| US6440465B1 (en) * | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
| US7670620B2 (en) | 2000-05-01 | 2010-03-02 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
| US20060165819A1 (en) * | 2000-05-01 | 2006-07-27 | Meisner Lorraine F | Topical composition for the treatment of psoriasis and related skin disorders |
| US20020164386A1 (en) * | 2000-05-01 | 2002-11-07 | Meisner Lorraine Faxon | Topical composition for the treatment of psoriasis and related skin disorders |
| US20100323986A1 (en) * | 2001-02-12 | 2010-12-23 | Marine Polymer Technologies, Inc., | Compositions and methods for modulation of vascular structure and/or function |
| US8859528B2 (en) | 2001-02-12 | 2014-10-14 | Marine Polymer Technologies, Inc. | Compositions and methods for modulation of vascular structure and/or function |
| US8481512B2 (en) | 2001-02-12 | 2013-07-09 | Marine Polymer Technologies, Inc. | Compositions and methods for modulation of vascular structure and/or function |
| US20030148998A1 (en) * | 2001-02-16 | 2003-08-07 | Cargill, Incorporated | Glucosamine and method of making glucosamine from microbial biomass |
| US7923437B2 (en) | 2001-02-16 | 2011-04-12 | Cargill, Incorporated | Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same |
| US8034925B2 (en) | 2001-02-16 | 2011-10-11 | Cargill, Incorporated | Glucosamine and method of making glucosamine from microbial biomass |
| US8222232B2 (en) | 2001-02-16 | 2012-07-17 | Cargill, Incorporated | Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass |
| US20060172392A1 (en) * | 2001-02-16 | 2006-08-03 | Cargill, Incorporated | Water soluble beta-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same |
| US20060178344A1 (en) * | 2001-02-16 | 2006-08-10 | Cargill, Incorporated | Glucosamine and N-acetylglucosamine and methods of making the same fungal biomass |
| US7816514B2 (en) | 2001-02-16 | 2010-10-19 | Cargill, Incorporated | Glucosamine and method of making glucosamine from microbial biomass |
| US20040077055A1 (en) * | 2001-02-16 | 2004-04-22 | Cargill, Incorporated | Glucosamine and method of making glucosamine from microbial biomass |
| US6693188B2 (en) | 2001-08-08 | 2004-02-17 | Cargill Incorporated | N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine |
| US20090099347A1 (en) * | 2002-04-02 | 2009-04-16 | Cargill, Incorporated | Chitosan production |
| US20050215774A1 (en) * | 2002-04-02 | 2005-09-29 | Trinkle Jamea R | Chitosan production |
| US7488812B2 (en) | 2002-04-02 | 2009-02-10 | Cargill, Incorporated | Chitosan production |
| US20050003023A1 (en) * | 2002-06-28 | 2005-01-06 | Meisner Lorraine Faxon | Topical composition for the treatment of psoriasis and related skin disorders |
| US20060058263A1 (en) * | 2002-11-01 | 2006-03-16 | Rogers Brent D | Heat pasturized liquids containing glucosamine |
| US20060246114A1 (en) * | 2002-11-01 | 2006-11-02 | Rogers Brent D | Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine |
| US20060003965A1 (en) * | 2002-11-01 | 2006-01-05 | Fosdick Lawrence D | N-acetyl-d-glucosamine (nag) supplemented food products and beverages |
| US20070178161A1 (en) * | 2003-03-27 | 2007-08-02 | Qiwang Xu | Use of n-acetryl-d-glucosamine in treating and controlling non-specific inflammations caused by physical or chemical factors |
| US8152750B2 (en) * | 2003-09-12 | 2012-04-10 | Marine Polymer Technologies, Inc. | Vascular access preservation in hemodialysis patients |
| US20050075597A1 (en) * | 2003-09-12 | 2005-04-07 | Vournakis John N. | Vascular access preservation in hemodialysis patients |
| US8992453B2 (en) | 2003-09-12 | 2015-03-31 | Marine Polymer Technologies, Inc. | Vascular access preservation in hemodialysis patients |
| US20090048210A1 (en) * | 2004-05-21 | 2009-02-19 | Saburo Minami | Agent for therapy or treatment of wound |
| US20060228320A1 (en) * | 2004-05-21 | 2006-10-12 | Saburo Minami | Agent for therapy or treatment of wound |
| WO2005112948A1 (en) * | 2004-05-21 | 2005-12-01 | Tottori University | Drug for remedy or treatment of wound |
| JPWO2005112948A1 (en) * | 2004-05-21 | 2008-03-27 | 国立大学法人鳥取大学 | Drugs for the treatment or treatment of wounds |
| US20070015822A1 (en) * | 2005-02-22 | 2007-01-18 | Peter Hanson | Methods for selectively treating COX-2 mediated disorders by administering gamma-tocopherol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3232836A (en) | Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine | |
| Bonadonna et al. | Clinical evaluation of adriamycin, a new antitumour antibiotic | |
| WOODWARD et al. | Management of typhoid fever and its complications | |
| US6986905B1 (en) | Pharmaceutical compositions for treating and saving and the method for the preparation thereof | |
| Kothari et al. | Pseudomonas cepacia septic arthritis due to intra-articular injections of methylprednisolone. | |
| Malpas et al. | Rubidomycin in acute leukaemia in adults | |
| US6720011B1 (en) | Injectable composition for cancer treatment | |
| JP2704546B2 (en) | ATLL therapeutic inhalant | |
| Alexander et al. | Fatal necrotizing fasciitis following suction-assisted lipectomy | |
| ATUK et al. | The use of potentially nephrotoxic antibiotics in the treatment of gram-negative infections in uremic patients | |
| JPH06501449A (en) | Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases | |
| Bornstein et al. | Serratia marcescens cellulitis in a patient on hemodialysis | |
| EP0811635B1 (en) | Intravascular membrane thickening inhibitor | |
| Lampkin et al. | Treatment of acute leukemia | |
| Robertson | Uracil mustard in the treatment of thrombocythemia | |
| US5051414A (en) | Inhibition of HIV and other retroviruses by polyoxoanions | |
| PULASKI et al. | Streptomycin in Surgical Infections: III. Otitis Externa, Otitis Media, Mastoiditis, Brain Abscess and Meningitis | |
| Movassaghi et al. | Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study Group | |
| JPH02243634A (en) | Medicine composition for recovering failure in myocardinal function after ischemia | |
| Davis et al. | Dicoumarin in Puerperal Thrombosis | |
| Willerson et al. | Septic arthritis, the unexpected complication | |
| Garvin | Renal complications due to sulfathiazole | |
| SOKOLOW et al. | Clinical evaluation of Cedilanid | |
| Martin et al. | Infections in pediatric surgery | |
| Black et al. | Coexistent Pulmonary Tuberculosis and Systemic Blastomycosis: Report of a Case Successfully Treated with Streptomycin, Para-Aminosalicylic Acid, and Stilbamidine |